Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab‐paclit...
Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab‐paclitaxel for non‐squamous non‐small cell lung cancer with malignant pleural effusion
About this item
Full title
Author / Creator
Tamiya, Motohiro , Tamiya, Akihiro , Suzuki, Hidekazu , Taniguchi, Yoshihiko , Katayama, Kanako , Minomo, Shojiro , Nakao, Keiko , Takeuchi, Naoko , Matsuda, Yoshinobu , Naito, Yujiro , Shiroyama, Takayuki , Okamoto, Norio , Okishio, Kyoichi , Kumagai, Toru , Atagi, Shinji , Imamura, Fumio and Hirashima, Tomonori
Publisher
New York: Springer US
Journal title
Language
English
Formats
Publication information
Publisher
New York: Springer US
Subjects
More information
Scope and Contents
Contents
Summary
Objectives
Vascular endothelial growth factor plays an important role in the pathogenesis of malignant pleural effusion (MPE). We previously showed the efficacy of bevacizumab (Bev) plus carboplatin (CBDCA)/paclitaxel (PTX) in the treatment of non-small lung cell cancer (NSCLC) with MPE. However, the toxicities were a little severe, a...
Alternative Titles
Full title
Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab‐paclitaxel for non‐squamous non‐small cell lung cancer with malignant pleural effusion
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2487157411
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2487157411
Other Identifiers
ISSN
0167-6997
E-ISSN
1573-0646
DOI
10.1007/s10637-021-01076-8
